CoChat
Sign Up
Cited by 127

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

GTPase Activity and Neuronal Toxicity of Parkinson's Disease–Associated LRRK2 Is Regulated by ArfGAP1

Stafa, Klodjan, Trancikova, Alzbeta, Webber, Philip J., Glauser, Liliane, West, Andrew B., Moore, Darren J.·2012·PLoS Genetics
DOI 10.1371/journal.pgen.1002526PMC PMC3280333
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pgen.1002526

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 72

  1. S Biskup, 2009, Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease., Biochim Biophys Acta, 1792, 625, 10.1016/j.bbadis.2008.09.015 · DOI
  2. T Gasser, 2009, Mendelian forms of Parkinson's disease., Biochim Biophys Acta, 1792, 587, 10.1016/j.bbadis.2008.12.007 · DOI
  3. DG Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study., Lancet Neurol, 7, 583, 10.1016/S1474-4422(08)70117-0 · DOI · Paper page
  4. S Lesage, 2006, LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs., N Engl J Med, 354, 422, 10.1056/NEJMc055540 · DOI · Paper page
  5. LJ Ozelius, 2006, LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews., N Engl J Med, 354, 424, 10.1056/NEJMc055509 · DOI
  6. WP Gilks, 2005, A common LRRK2 mutation in idiopathic Parkinson's disease., Lancet, 365, 415
  7. I Marin, 2008, The Roco protein family: a functional perspective., Faseb J, 22, 3103, 10.1096/fj.08-111310 · DOI
  8. CJ Gloeckner, 2006, The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity., Hum Mol Genet, 15, 223, 10.1093/hmg/ddi439 · DOI
  9. E Greggio, 2006, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin., Neurobiol Dis, 23, 329, 10.1016/j.nbd.2006.04.001 · DOI · Paper page
  10. AB West, 2005, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity., Proc Natl Acad Sci U S A, 102, 16842, 10.1073/pnas.0507360102 · DOI · Paper page
  11. Y Imai, 2008, Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila., Embo J, 27, 2432, 10.1038/emboj.2008.163 · DOI
  12. M Jaleel, 2007, LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity., Biochem J, 405, 307, 10.1042/BJ20070209 · DOI · Paper page
  13. F Gillardon, 2009, Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability–a point of convergence in parkinsonian neurodegeneration?, J Neurochem, 110, 1514, 10.1111/j.1471-4159.2009.06235.x · DOI
  14. T Kanao, 2010, Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila., Hum Mol Genet, 19, 3747, 10.1093/hmg/ddq289 · DOI
  15. A Kumar, 2010, The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation., PLoS ONE, 5, e8730, 10.1371/journal.pone.0008730 · DOI
  16. G Ito, 2007, GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease., Biochemistry, 46, 1380, 10.1021/bi061960m · DOI
  17. PA Lewis, 2007, The R1441C mutation of LRRK2 disrupts GTP hydrolysis., Biochem Biophys Res Commun, 357, 668, 10.1016/j.bbrc.2007.04.006 · DOI
  18. X Li, 2007, Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants., J Neurochem, 103, 238, 10.1111/j.1471-4159.2007.04743.x · DOI
  19. WW Smith, 2006, Kinase activity of mutant LRRK2 mediates neuronal toxicity., Nat Neurosci, 9, 1231, 10.1038/nn1776 · DOI · Paper page
  20. AB West, 2007, Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity., Hum Mol Genet, 16, 223, 10.1093/hmg/ddl471 · DOI · Paper page
  21. JM Taymans, 2011, LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding., PLoS ONE, 6, e23207, 10.1371/journal.pone.0023207 · DOI
  22. CJ Gloeckner, 2010, Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2., J Proteome Res, 9, 1738, 10.1021/pr9008578 · DOI
  23. E Greggio, 2009, The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites., Biochem Biophys Res Commun, 389, 449, 10.1016/j.bbrc.2009.08.163 · DOI
  24. S Kamikawaji, 2009, Identification of the autophosphorylation sites of LRRK2., Biochemistry, 48, 10963, 10.1021/bi9011379 · DOI
  25. PJ Webber, 2011, Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities., J Mol Biol, 412, 94, 10.1016/j.jmb.2011.07.033 · DOI
  26. K Haebig, 2010, ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2., PLoS ONE, 5, e13762, 10.1371/journal.pone.0013762 · DOI
  27. Y Xiong, 2010, GTPase activity plays a key role in the pathobiology of LRRK2., PLoS Genet, 6, e1000902, 10.1371/journal.pgen.1000902 · DOI
  28. V Daniels, 2011, Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant., J Neurochem, 116, 304, 10.1111/j.1471-4159.2010.07105.x · DOI
  29. C Iaccarino, 2007, Apoptotic mechanisms in mutant LRRK2-mediated cell death., Hum Mol Genet, 16, 1319, 10.1093/hmg/ddm080 · DOI
  30. WW Smith, 2005, Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration., Proc Natl Acad Sci U S A, 102, 18676, 10.1073/pnas.0508052102 · DOI
  31. CC Ho, 2009, The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration., J Neurosci, 29, 1011, 10.1523/JNEUROSCI.5175-08.2009 · DOI
  32. J Dusonchet, 2011, A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2., J Neurosci, 31, 907, 10.1523/JNEUROSCI.5092-10.2011 · DOI
  33. BD Lee, 2010, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease., Nat Med, 16, 998, 10.1038/nm.2199 · DOI · Paper page
  34. Y Li, 2009, Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease., Nat Neurosci, 12, 826, 10.1038/nn.2349 · DOI
  35. D MacLeod, 2006, The familial Parkinsonism gene LRRK2 regulates neurite process morphology., Neuron, 52, 587, 10.1016/j.neuron.2006.10.008 · DOI
  36. ED Plowey, 2008, Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells., J Neurochem, 105, 1048, 10.1111/j.1471-4159.2008.05217.x · DOI
  37. L Parisiadou, 2009, Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis., J Neurosci, 29, 13971, 10.1523/JNEUROSCI.3799-09.2009 · DOI
  38. E Cukierman, 1995, The ARF1 GTPase-activating protein: zinc finger motif and Golgi complex localization., Science, 270, 1999, 10.1126/science.270.5244.1999 · DOI
  39. W Liu, 2005, ArfGAP1 dynamics and its role in COPI coat assembly on Golgi membranes of living cells., J Cell Biol, 168, 1053, 10.1083/jcb.200410142 · DOI
  40. JG Donaldson, 1992, ADP-ribosylation factor, a small GTP-binding protein, is required for binding of the coatomer protein beta-COP to Golgi membranes., Proc Natl Acad Sci U S A, 89, 6408, 10.1073/pnas.89.14.6408 · DOI
  41. TC Taylor, 1992, Two distinct members of the ADP-ribosylation factor family of GTP-binding proteins regulate cell-free intra-Golgi transport., Cell, 70, 69, 10.1016/0092-8674(92)90534-J · DOI
  42. JG Donaldson, 2011, ARF family G proteins and their regulators: roles in membrane transport, development and disease., Nat Rev Mol Cell Biol, 12, 362, 10.1038/nrm3117 · DOI
  43. S Biskup, 2006, Localization of LRRK2 to membranous and vesicular structures in mammalian brain., Ann Neurol, 60, 557, 10.1002/ana.21019 · DOI
  44. T Hatano, 2007, Leucine-rich repeat kinase 2 associates with lipid rafts., Hum Mol Genet, 16, 678, 10.1093/hmg/ddm013 · DOI
  45. J Alegre-Abarrategui, 2009, LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model., Hum Mol Genet, 18, 4022, 10.1093/hmg/ddp346 · DOI
  46. A Parnis, 2006, Golgi localization determinants in ArfGAP1 and in new tissue-specific ArfGAP1 isoforms., J Biol Chem, 281, 3785, 10.1074/jbc.M508959200 · DOI
  47. T Kanao, 2010, Activation of FoxO by LRRK2 induces expression of proapoptotic proteins and alters survival of postmitotic dopaminergic neuron in Drosophila., Hum Mol Genet
  48. L Wang, 2008, The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2., J Neurosci, 28, 3384, 10.1523/JNEUROSCI.0185-08.2008 · DOI
  49. S Biskup, 2007, Dynamic and redundant regulation of LRRK2 and LRRK1 expression., BMC Neurosci, 8, 102, 10.1186/1471-2202-8-102 · DOI
  50. S Higashi, 2007, Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain., Brain Res, 1155, 208, 10.1016/j.brainres.2007.04.034 · DOI
  51. S Higashi, 2007, Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain., J Neurochem, 100, 368, 10.1111/j.1471-4159.2006.04246.x · DOI
  52. HT McMahon, 2004, COP and clathrin-coated vesicle budding: different pathways, common approaches., Curr Opin Cell Biol, 16, 379, 10.1016/j.ceb.2004.06.009 · DOI
  53. SY Lee, 2005, ARFGAP1 plays a central role in coupling COPI cargo sorting with vesicle formation., J Cell Biol, 168, 281, 10.1083/jcb.200404008 · DOI
  54. JS Yang, 2002, ARFGAP1 promotes the formation of COPI vesicles, suggesting function as a component of the coat., J Cell Biol, 159, 69, 10.1083/jcb.200206015 · DOI
  55. J Lippincott-Schwartz, 2006, Insights into COPI coat assembly and function in living cells., Trends Cell Biol, 16, e1, 10.1016/j.tcb.2006.08.008 · DOI
  56. R Beck, 2009, ArfGAP1 activity and COPI vesicle biogenesis., Traffic, 10, 307, 10.1111/j.1600-0854.2008.00865.x · DOI
  57. M Bai, 2011, ARFGAP1 promotes AP-2-dependent endocytosis., Nat Cell Biol, 13, 559, 10.1038/ncb2221 · DOI
  58. I Marin, 2006, The Parkinson disease gene LRRK2: evolutionary and structural insights., Mol Biol Evol, 23, 2423, 10.1093/molbev/msl114 · DOI
  59. J Deng, 2008, Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase., Proc Natl Acad Sci U S A, 105, 1499, 10.1073/pnas.0709098105 · DOI
  60. X Li, 2010, Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2., J Biol Chem, 285, 29569, 10.1074/jbc.M110.127639 · DOI
  61. S Sen, 2009, Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization., J Biol Chem, 284, 36346, 10.1074/jbc.M109.025437 · DOI
  62. Z Berger, 2010, Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation., Biochemistry, 49, 5511, 10.1021/bi100157u · DOI
  63. X Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein., Neuron, 64, 807, 10.1016/j.neuron.2009.11.006 · DOI
  64. N Shin, 2008, LRRK2 regulates synaptic vesicle endocytosis., Exp Cell Res, 314, 2055, 10.1016/j.yexcr.2008.02.015 · DOI
  65. G Piccoli, 2011, LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool., J Neurosci, 31, 2225, 10.1523/JNEUROSCI.3730-10.2011 · DOI
  66. A Meixner, 2011, A QUICK screen for Lrrk2 interaction partners–leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics., Mol Cell Proteomics, 10, M110 001172, 10.1074/mcp.M110.001172 · DOI
  67. P Beemiller, 2006, A phosphatidylinositol-3-kinase-dependent signal transition regulates ARF1 and ARF6 during Fcgamma receptor-mediated phagocytosis., PLoS Biol, 4, e162, 10.1371/journal.pbio.0040162 · DOI
  68. DJ Moore, 2008, Parkin mediates the degradation-independent ubiquitination of Hsp70., J Neurochem, 105, 1806, 10.1111/j.1471-4159.2008.05261.x · DOI
  69. RL Strack, 2008, A noncytotoxic DsRed variant for whole-cell labeling., Nat Methods, 5, 955, 10.1038/nmeth.1264 · DOI
  70. R Luthi-Carter, 2010, SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis., Proc Natl Acad Sci U S A, 107, 7927, 10.1073/pnas.1002924107 · DOI
  71. MC Herzig, 2011, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice., Hum Mol Genet, 20, 4209, 10.1093/hmg/ddr348 · DOI
  72. PJ Hallett, 2008, Biochemical fractionation of brain tissue for studies of receptor distribution and trafficking., Curr Protoc Neurosci Chapter, 1, Unit 1 16

Cited by

Sorted by citations

Metadata

Authors
Stafa, K., Trancikova, A., Webber, P. J., Glauser, L., West, A. B., & Moore, D. J.
Venue
PLoS Genetics
Publisher
Public Library of Science (PLoS)
Published
2012-02-09
Volume
8
Issue
2
Pages
e1002526
ISSN
1553-7404
DOI
10.1371/journal.pgen.1002526
PMC
PMC3280333
Cited by
127
References
2
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review